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Abstract Grb7 is a member of a family of molecular adapters
which are able to contribute positively but also negatively to
signal transduction and whose precise roles remain obscure. Rnd1
is a member of the Rho family, but, as opposed to usual
GTPases, it is constitutively bound to GTP. We show here that
Rnd1 and Grb7 interact, in two-hybrid assays, in vitro, and in
pull-down experiments performed with SK-BR3, a breast cancer
cell line that overexpresses Grb7. This interaction involves switch
II loop of Rnd1, a region crucial for guanine nucleotide exchange
in all GTPases, and a Grb7 SH2 domain, a region crucial for
Grb7 interaction with several activated receptors. The contribu-
tion of the interaction between Rnd1 and Grb7 to their respective
functions and properties is discussed.
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1. Introduction
Molecular adapters are involved in multiple protein/protein
interactions required to form the large multi-protein com-
plexes involved in signal transduction. In addition to the
Grb2/Nck prototypic family, a new kind of adapters has
emerged recently, the Grb7/10/14 family, where proteins are
made of combinations of four protein interaction domains.
Their Src homology-2 (SH2) domains recognize phosphotyr-
osines in an appropriate sequence context on activated tyro-
sine kinase receptors [1^3] and indeed Grb7 has been shown
to interact with the EGF receptor, with erbB2, 3 and 4, the
PDGF receptor and with Ret [1,4^7]. Grb7 can be phosphor-
ylated on serines and threonines [4] and becomes tyrosine
phosphorylated after ligand stimulation of erbB2 [4]. Grb7
also interacts with other signaling proteins such as Syp phos-
phatase [8] and Shc adapter protein [4]. Grb10 isoforms inter-
act with Ret [9], the ELK receptor [10], the IGF-1 receptor
and the insulin receptor [11,12]. Grb10 also binds non-recep-
tor tyrosine kinases such as BCR-ABL and Tec in a phospho-
tyrosine-dependent manner. This interaction leads to the
phosphorylation of Grb10 [13,14].
Last members of this family, Grb14 and its close relative
rGrb14, were found to interact with PDGF and insulin recep-
tors [3,15], inhibiting in the latter case insulin actions [15].
Interaction of Grb7/10/14 proteins with receptor phosphory-
lated on tyrosines could involve an additional region located
between the SH2 domain and the central pleckstrin homology
(PH) region. This domain called BPS (between PH and SH2
domains) [16] or PIR (phosphorylated insulin receptor-inter-
acting region) [15] could help to determine the speci¢city of
Grb7/10/14 interaction with di¡erent tyrosine kinase receptors
and/or modulate the strength of interactions with those recep-
tors.
Beside the SH2 and PIR domains, Grb7/10/14 proteins con-
tain, as the most N-terminal domain, a consensus proline-rich
SH3-binding motif. In vitro binding experiments have shown
a strong binding of full-length Grb10 to Abl SH3-GST fusion
polypeptide whereas no binding was detected on PI-3-kinase,
Grb2 and Fyn SH3 domains [17]. Finally, Grb7/10/14 harbor
a central pleckstrin homology (PH) domain. Another striking
feature of these Grb proteins is their putative implication in
oncogenesis. Grb7, mapped on 17q11.2-q12, was found to be
co-ampli¢ed with erbB2 in breast cancer cell lines and breast
cancer specimens [4]. The ¢nding that Grb7 and ErbB2 are
both overexpressed and bind tightly together suggests that
they participate to a common pathway involved in breast
epithelial cell transformation, contributing to a more aggres-
sive and invasive phenotype, since ErbB2 ampli¢cation has
been associated to more aggressive tumors [18,19].
Presumptions for a role of Grb7/10/14 in cell migration and
invasion came recently from the ¢nding that a splice variant
of Grb7, lacking the C-terminal SH2 domain, was overex-
pressed in metastatic lymph nodes as compared to the prim-
itive esophageal tumor tissue [20]. Expression of an antisense
Grb7 RNA lowers endogenous Grb7 protein levels and sup-
presses in vitro invasive phenotype of esophageal carcinoma
cells.
Cell migration involves diverse rearrangements of the cell
cytoskeleton. A class of proteins involved in these events be-
longs to the extensively studied Rho/Rac subfamily of small
GTP-binding proteins (reviewed in [21]). Micro-injection stud-
ies in Swiss 3T3 cells have indicated that Cdc42Hs, Rac1 and
RhoA proteins act in sequence to control the extension of
exploratory ¢lopodia (Cdc42), the larger extensions of lamel-
lipodia (Rac1) and attachment to substrate for traction by
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focal adhesions and stress ¢bers (RhoA) in motile mammalian
¢broblasts [22^25]. Rho proteins have been suggested to be
involved in invasive and metastatic capacities of tumor cells
[26,27].
Like Ras, Rho/Rac proteins cycle between a GDP bound
state and a GTP bound state; cycling between these two con-
formations is tightly regulated. The recently identi¢ed Rnd
proteins do not ¢t in this model: they are constitutively bound
to GTP [28]. Rnd1 shares 45% identity with RhoA, but key
amino acid substitutions are most likely the molecular basis
for Rnd1 extremely low intrinsic GTPase activities and its
presumed resistance to any GAP activity [28]. Interestingly,
overexpression of Rnd1 or of Rnd3/RhoE induces loss of
polymerized actin structures and focal adhesion, causing loss
of cell-matrix adhesion [28], and Rnd3/RhoE stimulates cell
migration speed of MDCK cells in the presence of HGF [29].
In this paper, we bring together Grb7 and Rnd1 by docu-
menting an interaction between these two proteins, raising the
question of a possible biological role of such an interaction in
growth factor-regulated cell motility and adhesion.
2. Materials and methods
2.1. Yeast strains and media
The Saccharomyces cerevisiae yeast reporter strain L40 (MATa
ade2 trp1 leu3 his3 LYS2: :lexA-HIS3 URA3: :lexA-lacz) and the
MATK yeast strain AMR70 [34] were handled according to standard
procedures [34,35]. The two-hybrid screen was performed essentially
as previously described by using a full-length Grb7 cDNA fused to
LexA-binding domain as bait, and a 9.5 day mouse embryo cDNA
library [36].
2.2. Plasmids
pRK5-Rnd1, pRK5-myc-Rnd1 and pRK5-myc-Rnd2 constructs
[28] and pVP16-Grb7 [8] were previously described. Grb7 cDNA
was subcloned in frame in pACTII two-hybrid vector at the BamH1
site (Clontech, Palo Alto, CA, USA). pGEX2T-SH2-Grb7, pGEX2T-
Grb7, Grb10, rGrb14 [15] and various deletants of Grb7 cDNA in
pACTII vector (Grb7KPH-PIR-SH2, Grb7KSH2, isolated SH2-Grb7,
Grb7KPIR-SH2, isolated PIR and isolated PIR-SH2) were kindly
provided by Dr. A.F. Burnol. Rnd1 and Rnd2 were cloned in frame
with LexA-binding domain in pVJL10 two-hybrid plasmid.
2.3. Immunoblotting and antibodies
Proteins were resolved by 10% or 12.5% SDS^PAGE, transferred to
nitrocellulose sheets by electroblotting, blocked with 5% non-fat milk
in phosphate-bu¡ered saline (PBS), containing 0,1% Tween 20 over-
night at +4‡C, subsequently probed with primary antibodies, then
incubated with horseradish peroxidase-conjugated secondary antibod-
ies as described [37]. After extensive washing, membranes were devel-
oped using a chemiluminescent reaction (ECL, Amersham corp.) ac-
cording to manufacturer’s instructions.
Rabbit polyclonal a⁄nity-puri¢ed anti-Grb7 antibodies sc-606 (C-
20) and sc-607 (N20) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) raised against a 20-mer C- or N-terminal, respectively, were
used at 1/200 dilution. Polyclonal rabbit anti-Rnd1 antibody ‘Pegase’
raised against the whole Rnd1 protein was previously described [28]
and used at 1/250 dilution. A rabbit polyclonal anti-Rnd1 antibody
raised against peptide 214-SELISSTFKKEKAKC-228 was used at
1:200 dilution and shown not to react with puri¢ed Rnd2 and
Rnd3 proteins (G. Zalcman, personal data). A goat polyclonal anti-
Rnd2 antibody (Santa-Cruz #sc-1945) was used at the same dilution
and was shown to only react with Rnd2 protein without any cross-
reactivity with puri¢ed bacterial or eukaryotic Rnd1 or Rnd3 proteins
(data not shown). Monoclonal anti-phosphotyrosine antibody PY20
and anti-myc 9E10 antibody were from Transduction Laboratories
and Boehringer Mannheim, respectively.
2.4. Cell culture and transfections
HeLa cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(Life Technologies Inc.) supplemented with 10% fetal calf serum,
1 mM glutamine, 100 mg/ml streptomycin, and 100 units/ml penicillin.
SK-BR3 human breast cancer cells overexpressing Grb7 by gene am-
pli¢cation [4] were kindly provided by Dr. P. de Cre¤moux and grown
in the same way. Cells were transfected with 10 Wg of pRK5-myc
(mock transfection), pRK5-myc-Rnd1 or pRK5-myc-Rnd2 con-
structs/100 mm dish using a modi¢ed calcium phosphate co-precipi-
tation method as described previously [37]. After transfection, cells
were grown for 36 h, after which cells from three 100 mm equivalent
culture dishes were lysed in 50 mM Tris^HCl pH 7.5, 150 mM NaCl,
5 mM MgCl2, 1 mM DTT, 1% Triton X-100, 0.5% NP-40 with a
cocktail of protease and phosphatase inhibitors, and centrifuged at
600Ug. The supernatants were used for Rnd expression analysis, GST
fusion protein binding and pull-down assays. Bacterial Rnd1 and
Rnd2 proteins were expressed as non-fusion proteins using pET11a
vector and produced as described [28], snap-frozen and stocked at
380‡C until being used. GST-Grb7, GST-SH2-Grb7 were produced
as previously described. SK-BR3 cell lysates were pre-cleared 30 min
at 4‡C on protein A/G Sepharose beads, and supernatants incubated
with either polyclonal anti-Rnd1 or anti-Rnd2 antibodies, in the pres-
ence of 100 ng of either bacterial Rnd1 or Rnd2 protein for 1 h at
4‡C. Immunocomplexes were incubated 1 h on protein A/G Sepharose
columns and then collected by centrifugation, extensively washed
three times in lysis bu¡er, and beads with bound proteins or super-
natants containing unbound proteins, resolved on SDS^PAGE and
immunoblotted with anti-Grb7 antibodies.
3. Results
3.1. Grb7 two-hybrid interaction with Rnd1
In an attempt to further characterize partners of Grb7
adapter protein, a two-hybrid screen was performed with a
full-length Grb7 protein fused to the LexA DNA-binding do-
main as a bait. One of the identi¢ed cDNAs encoded a trun-
cated form of Rnd1 [28], from amino acid 61 to amino acid
144. Although such a polypeptide would not bind guanine
nucleotides, it contains a loop present on the surface of Rho
proteins [30], the so-called switch II region, and the ‘rho insert
region’, both of which are involved in several e¡ector and
regulator interactions. In an attempt to check that the full-
length Rnd proteins could actually interact with Grb7, we
made a two-hybrid construct to express Rnd1 deleted only
of its C-terminal CSIM membrane localization peptide. This
construct gives a huge background in two-hybrid assays. An
accidentally generated mutant expressing the ¢rst 146 amino
acids of Rnd1 (Rnd1*) did not have any background in the
assay and did interact speci¢cally with Grb7. Such a mutant,
again, displays the switch II region and the so-called ‘rho
insert region’.
3.2. Mapping the Rnd-interacting domain on Grb7 protein
Since this interaction between a truncated Rnd1 protein and
Grb7 was puzzling, we tested the speci¢city of this interaction.
In a ¢rst series of assays, we mapped the region of Grb7 that
was involved. Two-hybrid constructs that express various do-
mains of Grb7 were tested. Surprisingly, the absence of only
the SH2 domain in Grb7 prevents Grb7 interaction with
Rnd1, while the SH2 domain of Grb7 alone binds to Rnd1
(Fig. 1). This result suggests that the SH2 domain of Grb7 is
necessary and su⁄cient for the interaction with Rnd1. Notice
that all positive interactions are detected with the mutated
Rnd1* and with wild-type full-length Rnd1, even if these lat-
ter interactions are weaker.
Secondly, we questioned the speci¢city for the SH2 domain
of Grb7 by testing several SH2 domains in the two-hybrid
assay.
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The Grb10 and Grb14 proteins, or their isolated SH2 do-
mains, failed to interact with Rnd1, despite approximately
70% amino acid identity with Grb7 in the SH2 domain. These
proteins, in the same two-hybrid test, retained the ability to
interact with the insulin receptor (Table 1).
SH2 or PTB domains from p85 phospho-inositol-3-kinase
(PI-3K), Phospholipase CQ (PLCQ), Src, Abl, Shc Nck, Grb2,
Aps-1, PTP-1D (Syp) and IRS-2 failed also to interact with
Rnd1 (Table 1). All of them were properly expressed as veri-
¢ed by their ability to interact with their respective natural
ligands in two-hybrid tests (cf. [31] and data not shown).
3.3. In vitro binding of full-length bacterially expressed Rnd1 to
Grb7 is direct and speci¢c
Rnd1 and Rnd2 proteins were expressed in bacteria as non-
fusion proteins as previously described, using the pET11a
vector. This procedure allows the puri¢cation of bacterially
expressed Rnd proteins at s 80% purity in a lysis bu¡er con-
taining GTP but without EDTA [28]. In such conditions, half
of the puri¢ed bacterial Rnd proteins were shown to bind
GTPKS [28]. GST protein, GST-Grb7 and GST-SH2-Grb7
fusion proteins were coupled to glutathione Sepharose beads
and then incubated with either Rnd1 or Rnd2 proteins. As
shown in Fig. 2, full-length Rnd1 protein but not Rnd2 inter-
acts with full-length Grb7 and with SH2-Grb7. None of the
Rnd proteins interacts with GST. These results con¢rm that
Rnd1 and Grb7 can interact and that most likely this inter-
action is direct. The interaction between Rnd1 and Grb7 ap-
pears also very speci¢c as under the same conditions Grb7
does not interact with the closely related Rnd2 protein.
Furthermore, the observation suggests that the interaction
is not dependent on tyrosine phosphorylation as all proteins
were puri¢ed from Escherichia coli.
3.4. In vitro binding of HeLa cell-expressed Rnd1 to Grb7 and
SH2-Grb7 does not require Rnd1 tyrosine phosphorylation
To further document the Grb7-Rnd1 interaction, we trans-
Table 1
Interaction of Rnd1 with various SH2-containing proteins
SH2 or PTB domains
fused to activation domain
RTK fused to LexA
(positive control)
LexA-Rnd1
p85 PI-3K +(c-Met) 3
PLCQ +(c-Met) 3
Src +(c-Met) 3
Abl +(c-Met) 3
Shc +(TrkA) 3
Nck +(IR) 3
Aps-1 +(IR) 3
PTP-1(Syp) +(c-Met) 3
IRS-2 +(IR) 3
Grb2 +(c-Met)
Grb10 +(IR) 3
Grb14 +(IR) 3
Grb7 +(c-Met) +
All SH2- or PTB-containing proteins used in this experiment were
checked for binding to at least one receptor tyrosine kinase (named
in between brackets) in a two-hybrid assay.
Fig. 1. Mapping the interacting domain on Grb7. Various regions of Grb7 corresponding to the proline-rich domain, the proline-rich domain
plus pleckstrin homology (PH) domain and Between pleckstrin and SH2 (BPS) domain, the SH2 domain, the proline-rich domain plus the PH
domain, the BPS domain and the BPS plus the PH domains were assayed for interaction with the Rnd1 fusion protein in a yeast two-hybrid
assay. All constructs containing the SH2 domain were able to interact with Rnd1 (lanes 1, 4 and 7). Constructs without SH2 domain were un-
able to interact with Rnd1 (lanes 2, 3, 5 and 6). The SH2 domain of Grb7 was necessary and su⁄cient for interaction with Rnd1 (lane 4).
Rnd1 F.L. refers to wild-type full-length Rnd1; Rnd1* refers to the mutated Rnd1 containing the ¢rst 146 amino acids.
Fig. 2. Speci¢c binding of Rnd1 to Grb7 is direct. To verify the in-
teraction observed in two-hybrid system, we produced in vitro GST-
Grb7 and GST-SH2 fusion proteins corresponding to the entire pro-
tein and to the SH2 domain of Grb7. Immobilized GST fusions
were incubated with puri¢ed Rnd1 or Rnd2 proteins expressed in
bacteria as non-fusion proteins using the pET11a vector. Proteins
bound to the beads were resolved by SDS^polyacrylamide gel elec-
trophoresis and subsequently immunoblotted with anti-Rnd antibod-
ies. No interaction was detected between Rnd2 protein and Grb7
constructs (left panel). Rnd1 was retained as well on GST-Grb7 as
on GST-SH2 beads (right panel). The speci¢c interaction between
Rnd1 and Grb7 is direct since both proteins are highly puri¢ed.
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fected HeLa cells with plasmids that allow expression of N-
terminally myc-tagged Rnd1 (pRK5-myc-Rnd1) and Rnd2
(pRK5-myc-Rnd2). Cell lysates were loaded 1 h on immobi-
lized GST fusion proteins or on immobilized GST alone as
control. Rnd1 and Rnd2 were present at equal concentrations
as checked by anti-myc (two right lanes) or speci¢c anti-Rnd
antibodies (data not shown).
As shown in Fig. 3, myc-Rnd1 was retained on an SH2-
Grb7 column (¢rst lane) whereas no myc-Rnd2 was found
bound to a same column (second lane).
To check whether the interaction between Grb7 and Rnd1
requires Rnd1 tyrosine phosphorylation, cell extracts of HeLa
cells transfected with pRK5-myc-Rnd1 (or pRK5-myc) were
incubated with GST-SH2, GST-Grb7 or GST beads and re-
solved by immunoblotting with anti-myc antibodies (Fig. 4A).
The proteins bound to GST and GST-Grb7 were submitted to
immunoblotting with anti-phosphotyrosine antibodies. No ty-
rosine phosphorylation is revealed on Rnd1, whereas higher
molecular weight phosphoproteins were detected in the GST-
Grb7 bound fraction, indicating that tyrosine phosphory-
lation actually occurred in HeLa transfected cells under our
experimental conditions (Fig. 4B). These high molecular
weight phosphoproteins retained on GST-Grb7 are likely to
be receptor tyrosine kinases previously shown to interact with
Grb7 [1,15]. Thus, Rnd1 tyrosine phosphorylation does not
seem to be required for Rnd1 to bind to the SH2 domain of
Grb7.
3.5. Interaction of endogenous Grb7 from SK-BR3 cells with
full-length Rnd1 protein
To test whether binding of Grb7 to Rnd1 could occur in
vivo, SK-BR3 cells, a breast cancer cell line that overexpresses
Grb7, were put to contribution. However, we could not detect
any endogenous Rnd1 proteins by Western blotting with spe-
ci¢c antibodies (data not shown). Transfection of these cells
with Rnd1 expression plasmids appeared to be insu⁄cient for
a robust expression of Rnd1, maybe because overexpression
of Rnd1 is deleterious for these cells, as has been shown for
Swiss 3T3 cells [28]. Not surprisingly, in such conditions no
co-immunoprecipitation of Grb7 and Rnd1 could be detected.
Therefore, we performed binding experiments with SK-BR3
cell extracts incubated with polyclonal anti-Rnd1 antibodies,
in the presence of 100 ng of either bacterially expressed Rnd1
or Rnd2 protein. Lysates were collected on protein A Sephar-
ose columns, and bound (lanes 2, 4, 6) or unbound proteins
(lanes 1, 3, 5) were tested by Western blot with anti-Grb7
antibodies. As shown in Fig. 5, endogenous Grb7 protein
was easily detected in SK-BR3 lysates (lanes 1, 3, 5, 7). Co-
immunoprecipitated Grb7 protein was only detected in lysates
incubated with anti-Rnd1 antibodies and Rnd1 bacterial pro-
tein (lane 4), but not in lysates incubated with anti-Rnd1 anti-
bodies but no Rnd1 protein (lane 6). Incubation with anti-
Rnd1 antibodies and Rnd2 protein leads to no precipitation
of Grb7 (lane 2). Incubation in presence of Rnd2 protein and
Fig. 3. The SH2 domain of Grb7 interacts with Rnd1 in vitro. We
tested the ability of the GST fusion proteins GST-Grb7 and GST-
SH2 to interact with Rnd proteins expressed in mammalian cells.
Immobilized GST fusions were incubated with lysates derived from
HeLa cells that were transfected with either control pRK5-myc or
pRK5-myc-Rnd1 or pRK5-myc-Rnd2. Proteins bound to the beads
were resolved by SDS^polyacrylamide gel electrophoresis and subse-
quently immunoblotted with anti-myc antibodies. The GST protein
alone showed no in vitro interaction with myc-Rnd1 or myc-Rnd2
(middle panel). Rnd1 interacts with GST-SH2 (¢rst lane) whereas
no interaction was detected with Rnd2 (second lane). Expression of
myc-Rnd1 and myc-Rnd2 was checked in total lysates (right two
lanes).
Fig. 4. Rnd1/Grb7 interaction does not require Rnd1 tyrosine phos-
phorylation. Immobilized GST fusions were incubated with lysates
derived from HeLa cells that were transfected with either control
pRK5-myc or pRK5-myc-Rnd1. Proteins bound to the beads were
resolved by SDS^polyacrylamide gel electrophoresis and subse-
quently immunoblotted with either anti-myc (panel A) or anti-phos-
photyrosine (panel B) antibodies. A: The GST protein alone
showed no in vitro interaction with myc-Rnd1 (right two lanes).
Rnd1 interacts as well with GST-SH2 (¢rst lane) as with GST-Grb7
(third lane). B: The proteins bound to GST and GST-Grb7 were
probed with anti-phosphotyrosine antibodies: no phosphorylation
was detected on Rnd1 (¢rst lane), despite presence of other tyro-
sine-phosphorylated proteins of higher molecular weight bound to
GST-Grb7. Thus myc-Rnd1 interacts with GST-Grb7 in a non-
phosphotyrosine-dependent manner.
Fig. 5. Interaction of endogenous Grb7 from SK-BR3 cells with
Rnd1. SK-BR3 breast cancer cell extracts were incubated with poly-
clonal anti-Rnd1 antibodies in the presence of 100 ng of either
Rnd1 or Rnd2 bacterial proteins. Lysates were collected on protein
A Sepharose columns and bound (lanes 2, 4, 6), unbound proteins
(lanes 1, 3, 5) and whole cell extracts (lane 7) were resolved by
SDS^polyacrylamide gel electrophoresis and subsequently immuno-
blotted with either anti-Grb7 antibodies. Endogenous Grb7 protein
was easily detected in unbound SK-BR3 lysates (lanes 1, 3, 5) and
in whole cell extracts (lane 7). Co-immunoprecipitated Grb7 was de-
tected in lysates incubated with anti-Rnd1 antibodies and Rnd1 pro-
tein (lane 4). Co-immunoprecipitated Grb7 was not detected when
Rnd2 protein was added instead of Rnd1 (lane 2) or when Rnd1
protein was omitted (lane 6).
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anti-Rnd2 antibodies leads to no Grb7 precipitation either
(data not shown).
4. Discussion
Rnd1, a member of the Rho family, has no GTPase activity
and appears constitutively GTP bound. Its overexpression in-
hibits stress ¢bers formation, but to what extent this property
re£ects its real function in tissue is not clear. Grb7 is an
adapter protein, member of the Grb7/10/14 family. The ge-
neric function of these proteins is not clear either, they have
been shown to participate positively but also negatively in
signal transduction (see for example [15]).
Here we show that Grb7 is able to speci¢cally interact with
Rnd1 protein. This interaction was shown to be direct and
involves the SH2 domain of Grb7 and a central part of Rnd1.
Surprisingly, the minimal Rnd1 region su⁄cient to interact
with Grb7 lacks the Rho e¡ector domain (switch I) and two
of the guanine-binding motifs. Preferential interactions with
truncated protein partners in the two-hybrid system have al-
ready been reported. For instance, the SH2 domain of Grb10
is unable to interact with the full-length Raf1 while it can bind
to the isolated amino-terminal domain of Raf1 in a two-hy-
brid assay. This observation led to the hypothesis that the
binding site of Raf1 is masked in the context of the whole
protein [32].
Modeling of Rnd1 structure, based on the GTP-locked
RhoA [30], suggests that the Grb7-interacting region contains
the switch II region of Rnd1. In the full-length protein, this
region could be in a conformation that does not favor the
binding of Grb7 and could be better exposed upon truncation.
Therefore, in a similar way to the two-hybrid Grb10/truncated
Raf1 interaction, the truncation in the Rnd1 two-hybrid clone
could explain the unmasking of a binding site for Grb7. In the
cell, this site might be unmasked by binding of a cellular
e¡ector on the ‘e¡ector region’, leading to a displacement of
the 310-helix 78RPL80. Such speculations remain to be con-
¢rmed by crystallographic studies of Rnd1/Grb7 complexes.
On the other hand, our biochemical experiments show that
Grb7 is able to interact with full-length Rnd1 protein. This
was shown in two di¡erent ways. Rnd1 puri¢ed from E. coli is
able to bind Grb7 expressed in mammalian cells. Grb7 ex-
pressed as a fusion protein in E. coli is able to bind both
Rnd1 made in E. coli and Rnd1 expressed in mammalian cells.
Again, two-hybrid deletion analysis that involves the SH2
domain of Grb7 as the Rnd1-binding site were validated by
in vitro binding assays.
No tyrosine phosphorylation was required for this interac-
tion as shown by the direct interaction of puri¢ed proteins
expressed in E. coli, and the absence of detectable tyrosine
phosphorylation on Rnd1 expressed in exponentially growing
HeLa cells. What could be the function of such a phospho-
tyrosine-independent SH2 interaction? Interactions between
Grb2 SH2 domain and non-phosphorylated ligands have
been previously reported but were shown to require a YXN
sequence [33]. In such a case, phosphorylation of the tyrosine
residue increased the strength of the interaction. A similar
peptide sequence (74YDN76, highly conserved in Rnd1,
Rnd2 and Rnd3) is present in the Grb7-interacting domain.
Thus, further experiments with Rnd1 peptides are required to
precisely map the Grb7 interaction motif.
In addition, the SH2 domain of Grb10 has also been shown
to interact with phosphorylated threonines or serines of both
Raf1 and MEK1 kinases, in a constitutive way for Raf1, but
in an insulin stimulation-dependent way for MEK1 [32]. Thus,
SH2-Grb7 interaction with Rnd1 could also involve serine
and threonine motifs in Rnd1, but no serine phosphorylation
was detected on GST-SH2-Grb7 bound Rnd1, using an anti-
phosphoserine antibody (data not shown).
Grb7 and Rnd1 mRNA are detected in liver and kidney
showing a restrictive pattern of overlapping tissue expression
[28]. Expression of myc-Rnd1 proteins in immortalized hepa-
tocyte cell lines, in HeLa cells or in breast cancer cell lines
(SK-BR3, BT474), led to disassembly of actin stress ¢bers,
and longer expression to loss of cell adhesion ([28] and our
unpublished data). Such events are a prerequisite for cell mi-
gration to take place. A presumptive role for Grb7 in invasive
growth has been proposed [20] and one might speculate that
the mechanism of invasiveness will involve a Grb7-Rnd1 link.
However, co-expression of Grb7 failed to interfere with stress
¢ber disassembly generated by Rnd1 expression (data not
shown). Thus, we could not determine yet whether Grb7 ac-
tually complexes with Rnd1 in a signalling module involved in
control of the actin cytoskeleton rearrangements. The exis-
tence of a stable or transient ternary complex involving a ty-
rosine kinase receptor (e.g. erbB2, EGF-R, PDGF-R), Grb7
and Rnd1 remains to be established. One can only speculate
about an inhibitory role for Grb7 in proliferation signalling
cascades initiated by membrane tyrosine kinase activation,
and to what extend this role will be played via interaction
with Rnd1 and interference with a Rho signalling cascade.
Such hypothesis is currently tested in cells exhibiting a migra-
tory phenotype after growth factor stimulation or epithelial
scar induction. Grb7 involvement in cell migration could be
the consequence of the recruitment of Rnd1. Alternatively,
Rnd1 binding to Grb7 might impair its interaction with other
molecular partners by steric hindrance. However, no two-hy-
brid interaction was detected between Rnd1 and several
known Rho/Rac e¡ectors or activators such as citron,
RhoA-interacting domain of Rock, lfc, mPak3 or rhotekin
(data not shown). Alternatively, Rnd1 might act upon Grb7
by interfering the interaction of this latter adapter with a
molecular partner by steric tra⁄c jam.
We have shown by di¡erent approaches that a Rnd1/Grb7
interaction can take place in vitro. These two proteins are
expressed in kidney and liver tissues. In liver, Rnd1 seems
to be located at the boundary of cell-cell contacts (GZ, pre-
liminary data) and Grb7, at least in tissue culture, was shown
to be relocalized at the plasma membrane after insulin and
growth factor stimulation. Unfortunately, we were unable to
detect endogenous Grb7 protein directly in liver sections.
However, we would like to propose that when cells are driven
to divide by growth factor stimulation, Grb7 relocalizes at the
membrane, in the same subcellular compartment as Rnd1,
where they could interact in vivo. The low level of expression
of both proteins and short life-time of Rnd1, as well as the
transient nature of the interaction might explain why we have
not been able to co-immunoprecipitate the endogenous pro-
teins. Alternatively, such an interaction could take place be-
tween closely related members of these families such as Rnd3/
RhoE and Grb10 or 14.
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